Establishing cost-effective allocation of proton therapy for patients with mediastinal Hodgkin lymphoma
08/08/2021
/
Publications
/
Dosimetry
IMRT
A health-economic study by the Jacksonville group. This study utilized (1) patient-level dosimetric information for a cost-effectiveness analysis using a Markov...
Does Proton Therapy Offer Demonstrable Clinical Advantages for Treating Thoracic Tumors?
04/04/2018
/
Publications
/
Dosimetry
A review by the MD Anderson group examined the available data with regard to proton therapy for thoracic malignancies, and presented the unique challenges in...
Proton Beam Therapy versus Photon Radiotherapy for Stage I Non-Small Cell Lung Cancer.
13/09/2022
/
Publications
/
Dosimetry
Published by the NCC group, Korea, this study reported clinical outcomes and dosimetry comparison of 289 patients with stage I NSCLC treated with protons (n=112...
FLASH Radiotherapy: What Can FLASH's Ultra High Dose Rate Offer to the Treatment of Patients With Sarcoma?
06/05/2024
/
Publications
/
FLASH Therapy
Dosimetry
Toxicity
A review article by the Upenn group summarized the preclinical and clinical evidence for the FLASH effect and discussed the potential clinical significance for...
Vision loss following high-dose proton-based radiotherapy for skull-base chordoma and chondrosarcoma
14/05/2021
/
Publications
/
Dosimetry
This study included148 chordoma and chondrosarcoma patients and 283 individual eyes with functional vision at baseline who received a minimum 30GyRBE to 0.1cm3...
Definitive high-dose, proton-based radiation for unresected mobile spine and sacral chordomas.
14/06/2022
/
Publications
/
Survival
Dosimetry
Sixty-seven patients with unresected spinal chordomas treated with PBT were evaluated. With a median follow-up of 56.2 months, 5- and 8-year OS were 83.5 % and...
Long-term outcomes of high-dose (74 GyE) proton beam therapy with concurrent chemotherapy for stage III nonsmall-cell lung cancer.
14/05/2021
/
Publications
/
Dosimetry
Toxicity
This study reported outcomes of 45 patients with stage III NSCLC treated with PBT of 74 GyE and concurrent chemotherapy. With a median follow-up time of 42.1...
Exposure of the heart in lung cancer radiation therapy: A systematic review of heart doses published during 2013 to 2020.
01/07/2022
/
Publications
/
Dosimetry
IMRT
Motion Management
Data of 140 dosimetry studies was analyzed. In the 105 non-SABR studies, the average MHD was similar between IMRT and 3DCRT (10.9 Gy versus 10.6 Gy) and lower...
ASTRO Radiation Therapy Summary of the ASCO Guideline on Management of Stage III Non-Small Cell Lung Cancer.
16/06/2023
/
Publications
/
Dosimetry
Based on the ‘Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline’, this summary document makes recommendations directly related to RT for the...
Cookies policy
If you continue browsing this website, you agree to the use of cookies in order to provide you with services and offers tailored to your own interests.
Manage your cookie preferences
Respect for your privacy is still a priority for us at IBA.
Functional cookies ensure that the website runs smoothly. They cannot be turned off. By setting your preferences, you can turn the use of these cookies on and off on our website, although these settings will only be valid on the device you are currently using.